Antibe Therapeutics
A publicly traded biotechnology company [ATE.TO; ATBPF] commercializing a breakthrough advance in the treatment of pain and inflammation.
Our drug pipeline targets large markets in the non-addictive management of pain. $ATE.TO $ATBPF
Primary market research with U.S. clinicians confirms high unmet need for safer non-opioid medications for acute pain.
$ATE.TO $ATBPF
Read the our latest press release here: https://loom.ly/NA7-tLE
$ATE.TO $ATBPF
To reduce opioid use, widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) in multimodal analgesia strategies has become standard of care -- otenaproxesul is a next-generation NSAID.
$ATE.TO $ATBPF
Read our latest press release here: https://loom.ly/YY6GvCE
$ATE.TO $ATBPF
“With widespread concerns about opioid misuse and addiction, there’s a notable shift towards prioritizing the creation of safer, non-addictive alternatives.”
To read the full Labiotech article featuring Antibe's Chief Medical Officer, Dr. Joe Stauffer, visit labiotech.eu/in-depth/new-non-opioid-pain-medication/.
$ATE.TO $ATBPF
New non-opioid pain medication: how is the biotech industry fighting pain after the opioid crisis? Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis.
Beginning with a commercial focus on post-operative pain, we plan to rapidly expand into other acute areas, including acute musculoskeletal pain, dysmenorrhea, migraine, gout, and dental pain.
$ATE.TO $ATBPF
Positioned as the non-opioid of choice for acute pain, otenaproxesul is headed into its Phase II trial next month – addressing a US $25+ billion market with no novel drugs introduced in 25 years...
$ATE.TO $ATBPF
Read the our latest press release here: antibethera.com/news/antibe-reports-q3-2024-interim-financial-and-operating-results
$ATE.TO $ATBPF
$ATE.TO $ATBPF
The research on hydrogen sulfide's therapeutic potential keeps growing... for the latest on its cardioprotective effects, see this recent paper in Cells: mdpi.com/2073-4409/13/2/158
$ATE.TO $ATBPF
Check out our new Corporate Presentation, including otenaproxesul's remaining path to approval on slide 28... find it at antibethera.com/investors/dashboard
We're excited to announce that Antibe has been named to the 2024 OTCQX Best 50, a ranking of the top performing companies traded on the OTCQX Best Market. Selected from more than 575 companies, Antibe is the only biotech to achieve this designation.
The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, the top tier of OTC-traded companies. The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year. Companies in the 2024 OTCQX Best 50 were ranked based on their performance in 2023.
As the opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed to treat acute pain. However, today's NSAIDs can cause gastrointestinal ulcers and bleeding, especially at the higher doses often employed in acute indications. Formulated to promote rapid onset of action, otenaproxesul is a non-opioid oral painkiller. Its Phase II trial is set to initiate in calendar Q1 2024, with top-line data expected in Q3 2024. With no novel oral pain drugs introduced since the late 1990s, there is urgent demand for alternatives to opioids to treat post-operative pain, acute musculoskeletal pain, dental pain and a range of other acute pain indications.
Watch as Ankit Bhargava, MD of Allele Capital joins Dan Legault, Chief Executive Officer of Antibe Therapeutics, and Dr. Joe Stauffer, the company's Chief Medical Officer, to discuss the benefits of otenaproxesul's new formulation, dive into Antibe's recently released data and Phase II planning, and explore the future of pain management.
Join us for A Conversation with Antibe Therapeutics... learn about the benefits of otenaproxesul's new formulation, dive into Antibe's recently released data and Phase II planning, and explore the future of pain management.
Our lead drug, otenaproxesul, is a non-opioid in clinical development for acute pain... targeting a $25 billion market that's seen no novel compounds introduced in 25 years.
With its Phase II trial set to launch this quarter, our next-generation NSAID aims to offer better GI safety while benefiting from a favorable cardiovascular profile.
To simulate drug effects on the liver, we use DILIsym, a sophisticated software model widely used to predict liver safety, As predicted by DILIsym, our recent clinical PK/PD study showed all envisioned acute pain treatment regimens to be liver-safe.
In light of the strong safety and PK data from otenaproxesul’s recent clinical PK/PD study, Antibe is upgrading the design of the upcoming Phase II trial. We're on track to initiate the trial next quarter with top-line results anticipated in calendar Q3 2024.
As an inflammation mediator, hydrogen sulfide can protect the digestive tract from NSAID-induced damage.
Learn about how gaseous mediators are being utilized in the next generation of anti-inflammatory drugs (co-authored by Antibe's founder Dr. John Wallace) frontiersin.org/articles/10.3389/fphar.2021.657457/full
$ATE.TO $ATBPF
Antibe's lead drug is a non-opioid painkiller targeting a wide range of acute pain indications.
$ATE.TO $ATBPF
A recent article in Barron's (a WSJ publication) speaks eloquently to the market opportunity for novel non-opioid painkillers:
"A nonaddictive pain pill that works as well as an opioid, with none of the same addiction risk and side effects, would be an instant blockbuster."
That's a good summary of otenaproxesul's target product profile.
To read more, click here: barrons.com/articles/vertex-pain-pill-non-opioid-573cae68 (paywalled but the first few lines provide a good overview). To hear Dan Legault, Antibe's CEO, in a recent interview that includes discussion of the Barron's article, click on this link https://cdn.jwplayer.com/previews/CmrZMZl9
$ATE.TO $ATBPF
Read our latest press release here:
antibethera.com/news/antibe-reports-q2-2024-interim-financial-and-operating-results
$ATE.TO $ATBPF
Read our latest press release here:
antibethera.com/news/antibe-reports-pk-results-of-first-clinical-study-of-otenaproxesuls-new-formulation
$ATE.TO $ATBPF
According to the NIH, postoperative pain is experienced by the vast majority of patients who undergo surgical procedures. Control of postoperative pain plays an essential role in facilitating a patient’s recovery to normal function and reduces the incidence of adverse physiologic and psychological effects associated with acute, uncontrolled pain.
$ATE.TO $ATBPF
Read our latest press release here:
antibethera.com/news/antibe-completes-first-clinical-study-of-otenaproxesuls-new-formulation
$ATE.TO $ATBPF
Click here to claim your Sponsored Listing.
Our Story
Antibe’s drug pipeline targets large markets in non-addictive pain management. Our lead drug, now in late Phase 2B trials, has demonstrated unprecedented safety in the treatment of chronic pain, a condition that affects hundreds of millions of people worldwide. Our second pipeline drug is designed to replace opioids for post-operative pain, directly addressing a worldwide public health crisis. In the longer term, we will exploit our platform to create drugs that address a range of inflammation-based diseases.
Videos (show all)
Category
Contact the business
Website
Address
15 Prince Arthur Avenue
Toronto, ON
M5R1B2
Toronto
www.earthcalm.ca started September 2007, is dedicated to promoting the healthiest, most sensible, most effective healing solution to EMFs available, anywhere..
16 Yonge Street
Toronto, M5E2A1
Trilex Laboratories is a playground where science and creativity meet to develop, research, and explore new ideas.
Toronto
Praedictum Bio is a Canadian company offering technologies to improve the health of our children
63 Galaxy Boulevard, Unit 1
Toronto, M9W5R7
Splice Biotechnics Inc. is a Toronto based healthcare product developer and biotech consulting firm.
Toronto, M5V2G3
Locke Bio develops new and scalable direct-to-consumer platforms that provide personalized healthcare for patients while creating value for every aspect of the pharmaceutical suppl...
Psyence Group Inc, 200 Bay Street
Toronto
Psyence Group is a life science biotechnology platform providing science forward natural products for psychedelic therapy, experience and wellness.
Toronto
At Elpida Therapeutics our main goal is to deliver Gene Therapies to patients in need.
63 Galaxy Boulevard, Unit 1
Toronto, M9W5R7
Splice Biotechnics specializes in non prescription drugs, natural health products and novel medical device development through cutting edge biotech and biomedical research. SHOP:...
Toronto
Our point-of-care devices will rapidly identify patients at-risk of adverse drug effects.
Toronto
Peptby peptide synthesis | Order High quality custom and premade research peptides at www.peptby.com
705 Progress Avenue
Toronto, M1H2X1
Welcome to Clinivex! Clinivex is a fast-growing ISO 9001:2015 certified worldwide leading manufacturer and supplier of high-quality, innovative research chemicals, pharmaceutical...
77 King Street West, Suite 2905
Toronto, M5K1H1
Ethnobotanical drug discovery company focused on R&D of mescaline-containing cacti.